Risk factors for losing hepatitis B virus surface antibody in patients with HBV surface antigen negative/surface antibody positive serostatus receiving biologic disease-modifying anti-rheumatic drugs: a nested case-control study.

Ming-Hui HungYa-Chih TienYing-Ming Chiu

Published in: Advances in rheumatology (London, England) (2021)

Besides lower baseline anti-HBs titer, chronic kidney disease also strongly predicts future anti-HBs negativity in patients with HBsAg-/anti-HBs+ serostatus who receive biologic DMARDs to treat rheumatic diseases. Patients with low anti-HBs titer (≤ 100 mIU/ml) and/or chronic kidney disease should be monitored during biologic DMARDs therapy, to enable timely prophylaxis to preempt potential HBV reactivation.

Keyphrases

hepatitis b virus
chronic kidney disease
rheumatoid arthritis
liver failure
end stage renal disease
systemic lupus erythematosus
climate change
peritoneal dialysis
smoking cessation
current status
cell therapy
drug induced